According to a media release issued by Bayer a couple of days ago, the combination of androgen deprivation therapy (ADT) + darolutamide (Nubeqa) extends overall survival “significantly” in men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, darolutamide, nmCRPC, non-metastatic, overall, survival | 2 Comments »
Bayer’s US pharmaceutical division has announced that the US Food and Drug Administration (FDA) has approved darolutamide — their formerly investigational androgen receptor inhibitor — for the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Bayer, castration-resistant, darolutamide, nmCRPC, non-metastatic, Nubeqa | 3 Comments »
The initial data from the ARCHES study of standard ADT + enzalutamide versus standard ADT + a placebo in men with metastatic, hormone-sensitive prostate cancer were reported earlier this year at the Genitourinary Cancers Symposium in San Francisco. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen, apalutamide, darolutamide, deprivation, enzalutamide | 7 Comments »
Earlier this year we had reported on the initial presentation of data demonstrating the efficacy and safety of darolutamide (formerly known as ODM-201), a third “super-antiandrogen” — similar to enzalutamide (Xtandi) and apalutamide (Erleada), in the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: castretaion-resistant, darolutamide, efficacy, nmCRPC, non-metastatic, safety | Leave a comment »
Also on Thursday in San Francisco, Dr. Karim Fizazi presented the initial results from the ARAMIS trial of darolutamide (formerly known as ODM-201) in the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: ARAMIS, castration-resistant, darolutamide, nmCRPC, non-metastatic, ODM-201 | 6 Comments »
Like other, similar drugs before it, ODM-201 — now properly known by the generic name darolutamide — has apparently hit the primary goal of metastasis-free survival in the Phase III ARAMIS trial, as announced yesterday by Bayer and Orion. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: castration-resistant, darolutamide, hormone-sensitive, metastatic, non-metastatic, ODM-201 | 4 Comments »
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
THE "NEW" PROSTATE CANCER INFOLINK